

PAH Pathways offers a wealth of resources including one-on-one support from PAH Pathways counselors in your area.
Learn more ยป
1. What is pulmonary arterial hypertension (PAH)?
Pulmonary arterial hypertension (PAH) is a disorder that affects the pulmonary arterythe large blood vessel that carries blood from the heart to the lungsand the hundreds of tiny blood vessels that branch off from it.
2. What are the different types of PAH?
The World Health Organization (WHO) recognizes five groups of pulmonary hypertension, the first of which is pulmonary arterial hypertension (PAH). WHO defines three types of PAH:
The good news is that research is ongoing and scientists and physicians know more about PAH today than they did 10 years ago. A cure has not yet been found, but progress has been made.2
* The World Health Organization is considered the international authority on health definitions and disease information. To learn more, visit the WHO website at www.who.int.
3. What are some typical symptoms of PAH?*
Some of the typical symptoms of PAH are caused by lack of oxygen and increased stress on the heart. These symptoms may not be obvious at first, but over time they may become more limiting. Without treatment, most patients will continue to experience increasing breathlessness and fatigue.3
Some symptoms of PAH are:* Tracleer and Ventavis do not improve all of these symptoms. Individual results may vary. For more information, consult the full prescribing information or visit the Tracleer and Ventavis websites.
There are different causes for PAH. In Inherited or Familial PAH, the disease is passed down genetically from your parents. Most cases of PAH occur in individuals with no known family history of the disorder. In fact, it is ten times more likely to be diagnosed with PAH because you have an underlying disease or medical condition than it is because you have a family member with PAH.4
5. What are endothelin and prostacyclin receptors?
Endothelin and prostacyclin are naturally occurring chemicals in the body.
Normal levels of endothelin help keep arteries open and elastic. Patients with PAH have high levels of endothelinsuggesting that endothelin may play a role in PAH.3 Endothelin receptor antagonists are designed to even out the imbalance of endothelin.
Prostacyclin keeps arteries open and suppresses excess cell growth and clotting. In PAH, production of prostacyclin is impaired, so there is not enough to keep arteries open.3
References: 1. Farber H, et al. Mechanisms of disease: pulmonary arterial hypertension. New Engl J Med. 2004;351:1655-1665 2. Gibbs J. Making a Diagnosis in PAH. Eur Respir Rev. 2007;16:102,8-12. 3. McLaughlin V, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006;114:1417-1431. 4. American Lung Association Web site. Available at: American Lung Association Web site.
Tracleer is indicated for patients with pulmonary arterial hypertension (PAH) WHO Class II-IV.
Tracleer Important Safety Information
Because of the risks associated with Tracleer, this medication may be prescribed only by your doctor through the Tracleer Access Program. Liver damage: Tracleer can cause serious liver damage, including in rare cases liver failure and, in situations with regular liver testing, unexplained liver cirrhosis. So you must have a blood test to check your liver function before you start Tracleer and each month after that. Call your doctor right away if you have any of these symptoms of liver problems: nausea, vomiting, fever, unusual tiredness, abdominal (stomach area) pain, or yellowing of the skin or whites of your eyes (jaundice). Serious birth defects: Tracleer is very likely to cause serious birth defects. It is important not to be or to become pregnant while taking Tracleer and to have a pregnancy test before you start the drug and each month thereafter. It is very important for you to use reliable forms of birth control while taking Tracleer. Hormonal contraceptives should not be used alone because they may not be effective in patients taking Tracleer.
Do not take Tracleer with glyburide or cyclosporine-A, because they may increase your chance for side effects.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
Important safety information about Ventavis
Because it lowers your blood pressure, Ventavis may cause dizziness, lightheadedness, and fainting. With Ventavis, the most common side effects are reddening of the face caused by dilation of blood vessels (flushing), increased cough, low blood pressure (hypotension), headaches, nausea, spasm of the jaw muscles that causes trouble opening your mouth, and fainting (syncope); other serious adverse events reported with the use of Ventavis include congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Before you start taking Ventavis, talk to your doctor to make sure you understand the side effects you might get.
Please see accompanying full Prescribing Information.